Takayasu's arteritis
Conditions
Interventions
Tocilizumab treatment group:Tocilizumab treatment group
Sponsors
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Males or non-pregnant female aged older than 18 years, fulfilled the TA classification criteria of the American College of Rheumatology (ACR), diagnosed with active disease state according to the National Institute of Health (NIH) criteria, whether they were treated by na?ve or not, and those who had never received TCZ before.
Exclusion criteria
Exclusion criteria: 1) un-controlled diabetes, hypertension before entry; 2) active digestive tract bleeding 3 months before entry; 3) history of or active primary or secondary immunodeficiency, and malignant diseases; 4) active infections that requires treatment or not, including bacteria, virus, fungi and mycobacteria infection; 5) neutrophil counts < 1.0×10^9/L, platelet counts < 100×10^9/L; 6) alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level?2 times the upper normal limit (UNL), serum creatinine level?1.5 UNL.^
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Erythrocyte sedimentation rate level before and after Tocilizumab treatment;hyper-sensitive C reactive protein before and after Tocilizumab treatment;Mural thickness of common carotid artery before and after Tocilizumab treatment;Mural thickness of subclavian artery before and after Tocilizumab treatment;Glucocoticoid dosage before and after Tocilizumab treatment;The adverse events of Tocilizumab; | — |
Countries
China
Contacts
Public ContactXinping TIAN
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital
Outcome results
None listed